LakeShore Biopharma Balance Sheet Health
Financial Health criteria checks 3/6
LakeShore Biopharma has a total shareholder equity of CN¥585.2M and total debt of CN¥417.5M, which brings its debt-to-equity ratio to 71.3%. Its total assets and total liabilities are CN¥1.5B and CN¥927.8M respectively.
Key information
71.3%
Debt to equity ratio
CN¥417.52m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥246.35m |
| Equity | CN¥585.21m |
| Total liabilities | CN¥927.82m |
| Total assets | CN¥1.51b |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: H6Z's short term assets (CN¥903.2M) exceed its short term liabilities (CN¥802.2M).
Long Term Liabilities: H6Z's short term assets (CN¥903.2M) exceed its long term liabilities (CN¥125.6M).
Debt to Equity History and Analysis
Debt Level: H6Z's net debt to equity ratio (29.3%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if H6Z's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: H6Z has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: H6Z has less than a year of cash runway if free cash flow continues to grow at historical rates of 9.1% each year.